Famotidine Tablets USP, 20 mg are available as beige, round, unscored, film-coated tablets, debossed with “5728” on one side and “TEVA” on the other side, containing 20 mg famotidine. Packaged in 30 count bottle.
Dispense in a well-closed, light-resistant container as defined in the USP, with a child-resistant closure (as required).
Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].
Avoid storage of famotidine tablets at temperatures above 40°C (104°F).
KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.
Central Nervous System (CNS) Adverse Reactions
Advise elderly patients and those with moderate and severe renal impairment of the risk of CNS adverse reactions, including confusion, delirium, hallucinations, disorientation, agitation, seizures, and lethargy
[see Warnings and Precautions (
. Report symptoms immediately to a healthcare provider.
Advise patients with moderate and severe renal impairment of the risk of QT interval prolongation
[ see Use in Specific Populations (
. Report new cardiac symptoms, such as palpitations, fainting and dizziness or lightheadedness immediately to a healthcare provider.
- Take famotidine tablets once daily before bedtime or twice daily in the morning and before bedtime, as recommended.
- Famotidine tablets may be taken with or without food.
- Famotidine tablets may be given with antacids.
Manufactured In Croatia By:
Pliva Hrvatska d.o.o.
Teva Pharmaceuticals USA, Inc.
North Wales, PA 19454
Rev. F 1/2019
|FAMOTIDINE famotidine tablet, film coated|
|Labeler — RedPharm Drug, Inc. (828374897)|
|RedPharm Drug, Inc.||828374897||repack (67296-1121), relabel (67296-1121)|
Revised: 01/2021 RedPharm Drug, Inc.
All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.